In partnership with FDA, industry and disease foundations, FNIH is creating a one-stop shop for data on the rare disease to spur diagnostics and therapeutics development
By exercising an option it acquired via its takeout of Celgene, BMS is paying $80 million for U.S. rights to an anti-tau asset for Alzheimer’s disease that Prothena believes could be best in